Galecto, Inc. (GLTO)

In October 2025, Galecto's stock surged by 750% due to retail investor interest, resembling a "meme stock rally." In November 2025, the stock tripled following the acquisition of Damora Therapeutics and a $285 million private investment. Guggenheim initiated coverage with a "Buy" recommendation and a $32.00 price target in December 2025, later raising it to $36.00, and Leerink Partners initiated coverage with an "Outperform" recommendation in January 2026. The consensus price target reached approximately $41.00 by mid-January 2026. Galecto reported its Q3 2025 earnings on November 6, 2025, with an EPS of -$2.36, and the stock price has shown considerable volatility, with a 52-week range between $2.01 and $38.33.

As a clinical-stage biotechnology company without commercialized products, demand seasonality is not applicable to Galecto, Inc.

Galecto, Inc. is a clinical-stage biotechnology company focused on developing novel therapeutics for severe diseases, particularly hematological cancers and liver diseases. Following the acquisition of Damora Therapeutics in late 2025, Galecto's pipeline expanded to focus on a mutant calreticulin (mut-CALR)-driven myeloproliferative neoplasm portfolio, targeting conditions like essential thrombocythemia and myelofibrosis. The company's lead asset, DMR-001, is a monoclonal antibody targeting mut-CALR, with an Investigational New Drug (IND) or equivalent filing anticipated in mid-2026, followed by first-in-human trials. Galecto's pipeline also includes GB3226, a preclinical dual inhibitor of ENL-YEATS and FLT3, being developed for multiple genetic subsets of acute myeloid leukemia (AML), and GB1211, an oral small molecule galectin-3 inhibitor, in development for various oncology indications and liver diseases.

Galecto, Inc. is headquartered in Copenhagen, Denmark, and maintains a presence in Boston, Massachusetts, United States.

Galecto, Inc. holds a "Moderate Buy" consensus rating from analysts, with an average rating score of 2.80, and scored higher than 74% of companies evaluated by MarketBeat in the medical sector. The acquisition of Damora Therapeutics and securing significant funding were positive developments, as was the appointment of experienced executives. However, the "meme stock rally" could be seen as a mixed event, and the failure of its Phase IIb GALACTIC-1 study for idiopathic pulmonary fibrosis in August 2023 prompted a re-evaluation of resource allocation.

Major institutional owners of Galecto, Inc. include Novo Holdings A/S, Connective Capital Management, LLC, Two Sigma Investments, LP, Vanguard Group Inc, and Renaissance Technologies LLC. Institutional share ownership increased by 42.84% quarter-over-quarter as of September 2025. Significant individual holders include Becker Hewes, Sherwin Sattarzadeh, and Paramora Holding LLC.